Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AcelRx Pharmaceuticals Inc receives complete response letter from FDA for new drug application for Zalviso


Friday, 25 Jul 2014 09:59pm EDT 

AcelRx Pharmaceuticals Inc and Grunenthal Group:Says that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).Says the company is currently reviewing the FDA's comments and requests contained in the CRL and plans to discuss these requests with the FDA. 

Company Quote

6.69
0.3 +4.69%
19 Dec 2014